{"id":937298,"date":"2026-02-17T12:02:24","date_gmt":"2026-02-17T17:02:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/"},"modified":"2026-02-17T12:02:24","modified_gmt":"2026-02-17T17:02:24","slug":"esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/","title":{"rendered":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040"},"content":{"rendered":"
\n

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur.<\/p>\n

The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN Pharmaceuticals Inc. (along with an affiliate); Renata Limited; and Sandoz Inc.) is ongoing, and there can be no assurance whether such ongoing patent litigation will allow a generic version of NEXLETOL and\/or NEXLIZET, as applicable, to be marketed in the U.S. prior to April 19, 2040.<\/p>\n

\n Esperion Therapeutics<\/strong>
\n
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare\/orphan disease therapies. The Company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.<\/p>\n

With a broad U.S. commercial infrastructure and global approvals across more than 40 countries, Esperion is well positioned to serve as a partner-of-choice for global innovators seeking U.S. market access through acquisition, in-license, co-promotion and revenue share opportunities. In tandem, the Company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases. For more information, visit esperion.com<\/u><\/a> and follow Esperion on LinkedIn<\/u><\/a> and X<\/u><\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, including the timing, designs and plans for the CLEAR Outcomes study and its results, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201csuggest,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201ccontinue,\u201d and similar expressions. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion\u2019s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion\u2019s commercial products, clinical activities and results, supply chain, commercial development and launch plans, business development, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion\u2019s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.<\/p>\n

\n Esperion Contact Information:<\/strong>
\n
Investors:
Alina Venezia
investorrelations@esperion.com<\/a>
(734) 887-3903<\/p>\n

Media:
Tiffany Aldrich
corporateteam@esperion.com<\/a>
(616) 443-8438<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN … <\/p>\n

Continue reading “Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-937298","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEsperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN … Continue reading "Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-17T17:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040\",\"datePublished\":\"2026-02-17T17:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/\"},\"wordCount\":591,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/\",\"name\":\"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=\",\"datePublished\":\"2026-02-17T17:02:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/","og_locale":"en_US","og_type":"article","og_title":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk","og_description":"ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolves the patent litigation brought by Esperion against Alkem in response to Alkem\u2019s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Alkem has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these types of agreements occur. The pending patent litigation against the remaining defendants (Aurobindo Pharma Limited (along with an affiliate); MSN … Continue reading \"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-17T17:02:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040","datePublished":"2026-02-17T17:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/"},"wordCount":591,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/","name":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=","datePublished":"2026-02-17T17:02:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY1NTM2NSM3NDI1NjEwIzIwMDcxNDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/esperion-reaches-settlement-agreement-with-fifth-anda-filer-not-to-market-generic-version-of-nexletol-bempedoic-acid-nexlizet-bempedoic-acid-ezetimibe-prior-to-april-19-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL\u00ae (bempedoic acid) & NEXLIZET\u00ae (bempedoic acid & ezetimibe) Prior to April 19, 2040"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937298","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=937298"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/937298\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=937298"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=937298"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=937298"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}